Literature DB >> 14757531

Conditional animal models: a strategy to define when oncogenes will be effective targets to treat cancer.

Sylvie Giuriato1, Karen Rabin, Alice C Fan, Catherine M Shachaf, Dean W Felsher.   

Abstract

The ability to model cancer in the mouse has provided a robust methodology to dissect the molecular etiology of cancer. These models serve as potentially powerful platforms to preclinically evaluate novel therapeutics. In particular, the recent development of strategies to conditionally induce the or knockout the function of genes in a tissue specific manner has enabled investigators to engineer mice to demonstrate that the targeted inactivation of specific oncogenes can be effective in inducing sustained regression of tumors. Thus, these animal models will be useful to define the specific genes that will be therapeutically useful to target for the treatment of particular human cancers.

Entities:  

Mesh:

Year:  2004        PMID: 14757531     DOI: 10.1016/j.semcancer.2003.11.002

Source DB:  PubMed          Journal:  Semin Cancer Biol        ISSN: 1044-579X            Impact factor:   15.707


  21 in total

Review 1.  An essential role for the immune system in the mechanism of tumor regression following targeted oncogene inactivation.

Authors:  Stephanie C Casey; Yulin Li; Dean W Felsher
Journal:  Immunol Res       Date:  2014-05       Impact factor: 2.829

Review 2.  The MYC oncogene is a global regulator of the immune response.

Authors:  Stephanie C Casey; Virginie Baylot; Dean W Felsher
Journal:  Blood       Date:  2018-03-07       Impact factor: 22.113

3.  Sustained regression of tumors upon MYC inactivation requires p53 or thrombospondin-1 to reverse the angiogenic switch.

Authors:  Sylvie Giuriato; Sandra Ryeom; Alice C Fan; Pavan Bachireddy; Ryan C Lynch; Matthew J Rioth; Jan van Riggelen; Andrew M Kopelman; Emmanuelle Passegué; Flora Tang; Judah Folkman; Dean W Felsher
Journal:  Proc Natl Acad Sci U S A       Date:  2006-10-20       Impact factor: 11.205

4.  RAS Interaction with PI3K: More Than Just Another Effector Pathway.

Authors:  Esther Castellano; Julian Downward
Journal:  Genes Cancer       Date:  2011-03

5.  Tumour maintenance is mediated by eNOS.

Authors:  Kian-Huat Lim; Brooke B Ancrile; David F Kashatus; Christopher M Counter
Journal:  Nature       Date:  2008-03-16       Impact factor: 49.962

Review 6.  MYC activation is a hallmark of cancer initiation and maintenance.

Authors:  Meital Gabay; Yulin Li; Dean W Felsher
Journal:  Cold Spring Harb Perspect Med       Date:  2014-06-02       Impact factor: 6.915

7.  Nanofluidic proteomic assay for serial analysis of oncoprotein activation in clinical specimens.

Authors:  Alice C Fan; Debabrita Deb-Basu; Mathias W Orban; Jason R Gotlib; Yasodha Natkunam; Roger O'Neill; Rose-Ann Padua; Liwen Xu; Daryl Taketa; Amy E Shirer; Shelly Beer; Ada X Yee; David W Voehringer; Dean W Felsher
Journal:  Nat Med       Date:  2009-04-12       Impact factor: 53.440

8.  Inhibition of HMGcoA reductase by atorvastatin prevents and reverses MYC-induced lymphomagenesis.

Authors:  Catherine M Shachaf; Omar D Perez; Sawsan Youssef; Alice C Fan; Sailaja Elchuri; Matthew J Goldstein; Amy E Shirer; Orr Sharpe; Joy Chen; Dennis J Mitchell; Maria Chang; Garry P Nolan; Lawrence Steinman; Dean W Felsher
Journal:  Blood       Date:  2007-07-10       Impact factor: 22.113

9.  Small interfering peptide (siP) for in vivo examination of the developing lung interactonome.

Authors:  J Craig Cohen; Erin Killeen; Avinash Chander; Ken-Ichi Takemaru; Janet E Larson; Kate J Treharne; Anil Mehta
Journal:  Dev Dyn       Date:  2009-02       Impact factor: 3.780

Review 10.  Inactivation of MYC reverses tumorigenesis.

Authors:  Y Li; S C Casey; D W Felsher
Journal:  J Intern Med       Date:  2014-07       Impact factor: 8.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.